ART Advanced Research Technologies Inc.

ART Advanced Research Technologies Inc.

November 28, 2007 08:56 ET

ART Advanced Research Technologies Appoints Rik van Heijningen to Lead European Commercialization of Optix Imaging System

MONTREAL, CANADA--(Marketwire - Nov. 28, 2007) - ART Advanced Research Technologies Inc. ("ART")(TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that Mr. Rik van Heijningen has joined the Company as Director of European Commercial Operations, Preclinical Imaging. With over 15 years of top-level sales, marketing, and management experience behind him, Mr. van Heijningen will lead the implementation of a commercial team to support the current and future Optix® customer base in Europe. His primary responsibility is to implement a results-oriented sales, service, and technical support team to grow market share for ART's preclinical imaging products. Prior to joining ART, Mr. van Heijningen was Vice President Commercial Operations at Kreatech Biotechnology BV, and held various leadership positions at Invitrogen BV and Dynal Biotech ASA, where he distinguished himself as a customer-focused manager.

"We are very pleased with our ability to recruit a person of Mr. van Heijningen's caliber to the ART team. His strong track record of developing and supporting a high technology user base gives us full confidence that he will lead ART's direct commercial effort effectively in Europe," said Sebastien Gignac, President and CEO of ART.

Dino DiCamillo, ART's Vice President of Global Sales and Marketing, Preclinical Imaging, added: "The appointment of Mr. van Heijningen is a critical step in the implementation of our commercial strategy of distributing our preclinical molecular imaging solution directly to the customers in Europe. It is our intention to provide world class service and application assistance to enable our European Optix users to fully utilize the potential of optical imaging in their research program."

Mr. van Heijningen commented: "I am very excited to take on this opportunity to lead ART's European commercial effort in preclinical imaging. I had the opportunity to meet many of ART's users at a recent User Meeting organized with GE Healthcare in France, and saw first hand the promise of molecular imaging in basic research, drug discovery and development. I look forward to continuing to advance ART's market position and implement a successful team to support our customer base."

About Rik van Heijningen

Prior to joining ART, Rik van Heijningen spent the last 20 years in the research, discovery, and preclinical market arena. He has held diverse sales, marketing, and business leadership roles in Europe, including Interim Vice President Commercial Operations of Kreatech Biotechnology BV in The Netherlands, and high ranking positions of Senior Sales Manager, General Manager for Germany, and Interim Vice President Tissue Typing, at the various European sites of Dynal Biotech LLC, where he was an integral part of the commercial team that ran a business of EUR 12 to 16 million. Mr. van Heijningen was also a Clinical Oncology Research Technician at the Academic Hospital of the Free University, Amsterdam, The Netherlands. Mr. van Heijningen holds a MBA from the University of Birmingham, England, and has completed university studies in biochemistry.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART in North America and Europe and is used by industry and academic leaders worldwide. The SoftScan® optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (

Contact Information